Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should b...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/10/1936 |
| _version_ | 1827678435204399104 |
|---|---|
| author | Yi-Sheng Sun Jing-Jing Zhou Han-Ping Zhu Fang Xu Wen-Bin Zhao Hang-Jing Lu Zhen Wang Shu-Qing Chen Ping-Ping Yao Jian-Min Jiang Zhan Zhou |
| author_facet | Yi-Sheng Sun Jing-Jing Zhou Han-Ping Zhu Fang Xu Wen-Bin Zhao Hang-Jing Lu Zhen Wang Shu-Qing Chen Ping-Ping Yao Jian-Min Jiang Zhan Zhou |
| author_sort | Yi-Sheng Sun |
| collection | DOAJ |
| description | The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should be developed in the future. The receptor binding domain (RBD), located at the S protein of SARS-CoV-2, contains most of the neutralizing epitopes. However, the immunogenicity of RBD monomers is not strong enough. In this study, we fused the RBD-monomer with a modified Fc fragment of human IgG1 to form an RBD-Fc fusion protein. The recombinant vaccine candidate based on the RBD-Fc protein could induce high levels of IgG and neutralizing antibody in mice, and these could last for at least three months. The secretion of IFN-γ, IL-2 and IL-10 in the RBD-stimulated splenocytes of immunized mice also increased significantly. Our results first showed that the RBD-Fc vaccine could induce both humoral and cellular immune responses and might be an optional strategy to control COVID-19. |
| first_indexed | 2024-03-10T06:08:12Z |
| format | Article |
| id | doaj.art-1d12d686d4d24136808169d495f634d4 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T06:08:12Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-1d12d686d4d24136808169d495f634d42023-11-22T20:18:19ZengMDPI AGViruses1999-49152021-09-011310193610.3390/v13101936Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Yi-Sheng Sun0Jing-Jing Zhou1Han-Ping Zhu2Fang Xu3Wen-Bin Zhao4Hang-Jing Lu5Zhen Wang6Shu-Qing Chen7Ping-Ping Yao8Jian-Min Jiang9Zhan Zhou10Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaKey Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, ChinaZhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaThe novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should be developed in the future. The receptor binding domain (RBD), located at the S protein of SARS-CoV-2, contains most of the neutralizing epitopes. However, the immunogenicity of RBD monomers is not strong enough. In this study, we fused the RBD-monomer with a modified Fc fragment of human IgG1 to form an RBD-Fc fusion protein. The recombinant vaccine candidate based on the RBD-Fc protein could induce high levels of IgG and neutralizing antibody in mice, and these could last for at least three months. The secretion of IFN-γ, IL-2 and IL-10 in the RBD-stimulated splenocytes of immunized mice also increased significantly. Our results first showed that the RBD-Fc vaccine could induce both humoral and cellular immune responses and might be an optional strategy to control COVID-19.https://www.mdpi.com/1999-4915/13/10/1936COVID-19RBD-Fcfusion proteinvaccineneutralizing antibodycellular immune response |
| spellingShingle | Yi-Sheng Sun Jing-Jing Zhou Han-Ping Zhu Fang Xu Wen-Bin Zhao Hang-Jing Lu Zhen Wang Shu-Qing Chen Ping-Ping Yao Jian-Min Jiang Zhan Zhou Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 Viruses COVID-19 RBD-Fc fusion protein vaccine neutralizing antibody cellular immune response |
| title | Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 |
| title_full | Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 |
| title_fullStr | Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 |
| title_full_unstemmed | Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 |
| title_short | Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2 |
| title_sort | development of a recombinant rbd subunit vaccine for sars cov 2 |
| topic | COVID-19 RBD-Fc fusion protein vaccine neutralizing antibody cellular immune response |
| url | https://www.mdpi.com/1999-4915/13/10/1936 |
| work_keys_str_mv | AT yishengsun developmentofarecombinantrbdsubunitvaccineforsarscov2 AT jingjingzhou developmentofarecombinantrbdsubunitvaccineforsarscov2 AT hanpingzhu developmentofarecombinantrbdsubunitvaccineforsarscov2 AT fangxu developmentofarecombinantrbdsubunitvaccineforsarscov2 AT wenbinzhao developmentofarecombinantrbdsubunitvaccineforsarscov2 AT hangjinglu developmentofarecombinantrbdsubunitvaccineforsarscov2 AT zhenwang developmentofarecombinantrbdsubunitvaccineforsarscov2 AT shuqingchen developmentofarecombinantrbdsubunitvaccineforsarscov2 AT pingpingyao developmentofarecombinantrbdsubunitvaccineforsarscov2 AT jianminjiang developmentofarecombinantrbdsubunitvaccineforsarscov2 AT zhanzhou developmentofarecombinantrbdsubunitvaccineforsarscov2 |